PubMed Health⌕ Search

Biomedical subjects

Neil R M Buist

Publications and source records attributed to Neil R M Buist.

4 recordsLinked to original sources

Contrasting phenotypes in three patients with novel mutations in mitochondrial tRNA genes.

We studied three patients, each harboring a novel mutation at a highly conserved position in a different mitochondrial tRNA gene. The mutation in patient 1 (T5543C) was associated with isolated mitochondrial myopathy, and occurred in the anticodon loop of tRNA(Trp). In patient 2, with mitochondrial myopathy and marked retinopathy, the mutation (G14710A) resulted in an anticodon swap (Glu to Lys) in tRNA(Glu). Patient 3, who manifested mitochondrial encephalomyopathy and moderate retinal dysfunction, harbored a mutation (C3287A) in the TpsiC loop of tRNA(Leu(UUR)). The mutations were heteroplasmic in muscle in all cases, and sporadic in two cases. PCR-RFLP analysis in all patients showed much higher amounts of mutated mtDNA in affected tissue (muscle) than unaffected tissue (blood), and significantly higher levels of mutated mtDNA in cytochrome c oxidase (COX)-negative muscle fibers than in COX-positive fibers, confirming the pathogenicity of these mutations. The mutation was also detected in single hair roots from all three patients, indicating that each mutation must have arisen early in embryonic development or in maternal germ cells. This suggests that individual hair root analyses may reflect a wider tissue distribution of mutated mtDNA than is clinically apparent, and might be useful in predicting prognosis and, perhaps, the risk of transmitting the mutation to offspring. Our data suggest a correlation between clinical phenotype and distribution of mutated mtDNA in muscle versus hair roots. Furthermore, the high threshold for phenotypic expression in single muscle fibers (92-96%) suggests that therapies may only need to increase the percentage of wild-type mtDNA by a small amount to be beneficial.

Adult↗

Metabolic evaluation of infantile epilepsy: summary recommendations of the Amalfi Group.

The purpose of this symposium was to bring together the disciplines of clinical neurology and metabolic investigation and to present the most up-to-date information about specific metabolic disorders associated with infantile epilepsy. Understanding the etiology of seizures is the key to rational intervention. It is only with this insight that progress in the treatment of these patients can be made. In the past, many infantile epileptic syndromes were described by their clinical features, without understanding of the underlying pathophysiology. In the future, it is hoped that the genetic and metabolic bases of these syndromes will be more completely defined such that reliable diagnostic and effective treatment methods are available. Most of the tests listed in Table 2 should not be performed without due consideration of the history, clinical findings, and results of prior studies. This article is intended to aid clinicians in reviewing potential metabolic diagnoses and to approaching metabolic evaluations in an economical, logical, and comprehensive manner. Although the field of metabolic diseases may be in its infancy, many of these disorders can be identified and treated. The task for investigators is to provide the armamentarium of diagnostic tools to clinicians to ensure that a metabolic disorder is not overlooked. There must be a common ground that links clinicians and basic researchers in an evolving and collaborative manner.

Clinical Laboratory Techniques↗